Latanoprost does not affect immune privilege of corneal allografts

Experimental Eye Research

Volumn 86, Issue 2, 2008, Pages 394-402

  Wang, Mingcong ^a   Kitahara, Yuki ^a   Yoshida, Atsushi ^b   Hori, Junko ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b TEIKYO UNIVERSITY HOSPITAL   (Japan)

Author keywords

ACAID; corneal neovascularization; corneal transplantation; immune privilege; latanoprost

Indexed keywords

CD11 ANTIGEN; DIMETHYL SULFOXIDE; LATANOPROST; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROSTAGLANDIN E2;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA TRANSPLANTATION; DRUG INHIBITION; DRUG MECHANISM; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; ANTERIOR CHAMBER; ANTIGEN-PRESENTING CELLS; ANTIHYPERTENSIVE AGENTS; CORNEA; CORNEAL TRANSPLANTATION; DINOPROSTONE; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNE TOLERANCE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROSTAGLANDINS F, SYNTHETIC;

EID: 39149102486     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2007.11.012     Document Type: Article

References (40)

1. Aihara M., Lindsey J.D., and Weinreb R.N. Reduction of intraocular pressure mouse eyes treated with latanoprost. Invest. Ophthalmol. Vis. Sci. 43 (2002) 146-150
2. Boisjoly H.M., Tourigny R., Bazin R., Laughrea P.A., Dubé I., Chamberland G., Bernier J., and Roy R. Risk factors of corneal graft failure. Ophthalmology 100 (1993) 1728-1735
3. Camras C.B., Toris C.B., and Tamesis R.R. Efficacy and adverse effects of medication used in the treatment of glaucoma. Drugs Aging 15 (1999) 377-388
4. Crowston J.G., Aihara M., Lindsey J.D., and Weinreb R.N. Effect of latanoprost on outflow facility in the mouse. Invest. Ophthalmol. Vis. Sci. 45 (2004) 2240-2245
5. Crowston J.G., Lindsey J.D., Aihara M., and Weinreb R.N. Effect of latanoprost on intraocular pressure in mice lacking the prostaglandin FP receptor. Invest. Ophthalmol. Vis. Sci. 45 (2004) 3555-3559
6. Daugschies A., and Ruttkowski B. Modulation of migration of Oesophagostomum dentatum larvae by inhibitors and products of eicosanoid metabolism. Int. J. Parasitol. 28 (1998) 355-362
7. David B. Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants. Am. J. Ophthalmol. 86 (1978) 455-461
8. Eakins K. Prostaglandins and non-prostaglandin mediated breakdown of the blood-aqueous barrier. Exp. Eye Res. 25 (1977) 483-498
9. Fechtner R.D., Khouri A.S., Zimmerman T.J., Bullock J., Feldman R., Kuljarni P., Michael A.J., Realini T., and Warwar R. Anterior uveitis associated with latanoprost. Am. J. Ophthalmol. 126 1 (1998) 37-41
10. Franca E.T., Arcieri E.S., Arcieri R.S., and Rocha F.J. A study of glaucoma after penetrating keratoplasty. Cornea 21 3 (2002) 284-288
11. 2. Invest. Ophthalmol. Vis. Sci. 45 (2004) 892-899
12. Hamrah P., Liu Y., Zhang Q., and Dana M.R. The corneal stroma is endowed with a significant number of resident dendritic cells. Invest. Ophthalmol. Vis. Sci. 44 (2003) 581-589
13. Hori J., and Streinlein J.W. Role of recipient epithelium in promoting survival of orthotopic corneal allograft in mice. Invest. Ophthalmol. Vis. Sci. 42 (2001) 720-726
14. Hori J., Wang M., Miyashita M., Tanemoto K., Takahashi H., Takemori T., Okumura K., Yagita H., and Azuma M. B7-H1-induced apoptosis as a mechanism of immune privilege of the eye. J. Immunol. 177 9 (2006) 5928-5935
15. 2α-isopropyl ester analogues for glaucoma treatment. Jpn. J. Ophthalmol. 37 (1993) 259-269
16. Ing J.J., Ing H.H., Nelson L.R., Hodge D.O., and Bourne W.M. Ten-year postoperative results of penetrating keratoplasty. Ophthalmology 105 (1998) 1855-1865
17. 2 on mesangial cell migration. Am. J. Nephrol. 15 (1995) 300-305
18. Jonuleit H., Kuhn U., Muller G., Steinbrink K., Paragnik L., Schmitt E., Knop J., and Enk A.H. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27 (1997) 3135-3142
19. Kaufman H.E., Varnell E.D., and Thompson H.W. Am. J. Ophthalmol. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit 127 5 (1999) 531-536
20. Kosaka T., Mishima H., Kiuchi Y., and Kataoka K. The effects of prostaglandins on the blood-ocular barrier. Jpn. J. Ophthalmol. 39 (1995) 368-375
21. Linden C., and Alm A. The effect on intraocular pressure of latanoprost once or four times daily. Br. J. Ophthalmol. 85 (2001) 1163-1166
22. Liu Y., Hamrah P., Zhang Q., Taylor A.W., and Dana M.R. Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive dendritic cells derived from MHC class-negative grafts. J. Exp. Med. 195 (2002) 259-268
23. Luft T., Jefford M., Luetjens P., Toy T., Hochrein H., Masterman K.A., Maliszewski C., Shortman K., Cebon J., and Maraskovsky E. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood 100 (2002) 1362-1372
24. Maguire M.G., Stark W.J., Gottsch J.D., Stulting R.D., Sugar A., Fink N.E., and Schwartz A. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Ophthalmology 101 (1994) 1536-1547
25. Miyake K., Ota I., Maekubo K., Ichihashi S., and Miyake S. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch. Ophthalmol. 117 (1999) 34-40
26. Niederkorn J.Y. The immunology of corneal transplantation. Dev. Ophthalmol. 30 (1999) 129-140
27. Sacca S., Pascotto A., Siniscalchi C., and Rolando M. Ocular complications of latanoprost in uveitic glaucoma: three case reports. J. Ocular Pharmacol. Ther. 17 (2001) 107-113
28. Sano Y., Ksander B.R., and Streilein J.W. Minor H, rather than MHC, alloantigens offer the greater barrier to successful orthotopic corneal transplantation in mice. Transplant Immunol. 4 (1996) 53-56
29. Sano Y., Okamoto S., and Streilein J.W. Induction of donor-specific ACAID can prolong orthotopic corneal allograft survival in "high-risk" eye. Curr. Eye Res. 16 (1997) 1171-1174
30. Scandella E., Men Y., Gillessen S., Forster R., and Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 100 (2002) 1354-1361
31. 2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem. 61 (2001) 18075-18081
32. Smith R.S., Zabaleta A., Savinova O.V., and John S.W. The mouse anterior chamber angle and trabecular meshwork develop without cell death. BioMed. Central Dev. Biol. 1 (2001) 3
33. Sonoda Y., and Streilein J.W. Impaired cell-mediated immunity in mice bearing healthy orthotopic corneal allografts. J. Immunol. 150 (1993) 1727-1734
34. Stein-Streilein J., and Strelein J.W. Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy. Int. Rev. Immunol. 21 (2002) 123-152
35. Streilein J.W. Immunoregulatory mechanisms of the eye. Retinal Eye Res. 18 (1999) 357-370
36. Streilein J.W. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat. Rev. Immunol. 3 (2003) 879-889
37. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology 100 (1993) 1297-1304
38. Warwar R.E., Bullock J.D., and Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 105 (1998) 263-268
39. Williams K.A., Roder D., Esterman A., Muehlberg S.M., and Coster D.J. Factors predictive of corneal graft survival: report from the Australian corneal graft registry. Ophthalmology 99 (1992) 403-414
40. Wilson S.E., and Kaufman H.E. Graft failure after penetrating keratoplasty. Surv. Ophthalmol. 34 (1990) 325-356